J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
Circle Pharma and Verismo feature in coveted sessions.
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
Single, double and even triple-payload ADCs will be presented at the meeting.
The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
Talapro-3 could help move Talzenna into earlier prostate cancer.
